NEW
HAVEN, Conn., May 9, 2022
/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
(NYSE: BHVN), a commercial-stage biopharmaceutical company
with a portfolio of innovative, late-stage product candidates
targeting neurological and neuropsychiatric diseases, plans to hold
its upcoming first quarter 2022 earnings call and webcast,
reporting financial results for the quarter ended March 31, 2022, and provide a review of recent
accomplishments and anticipated upcoming milestones, on
Wednesday, May 11, 2022 at
8:30 a.m. ET. The
earnings call and webcast will follow Biohaven's issuance of its
first quarter 2022 earnings release and the filing of its quarterly
report on Form 10-Q for the quarter ended March 31, 2022 on Tuesday,
May 10, 2022.
To access the call on May 11,
2022, please dial 877-407-9120 (domestic) or 412-902-1009
(international). The conference call webcast and accompanying slide
presentation can be accessed through the "Investors" section of
Biohaven's website at www.biohavenpharma.com. To ensure a timely
connection, it is recommended that participants register at least
15 minutes prior to the scheduled webcast. A replay of the call
will be made available for two weeks following the conference call.
To hear a replay of the call, dial 877-660-6853 (domestic) or
201-612-7415 (international) with conference ID 13728089. An
archived webcast will be available on Biohaven's website.
About Biohaven
Biohaven is a global
commercial-stage biopharmaceutical company with a portfolio of
innovative, best-in-class therapies to improve the lives of
patients with debilitating neurological and neuropsychiatric
diseases, including rare disorders. Biohaven's
Neuroinnovation™ portfolio includes FDA-approved
Nurtec® ODT (rimegepant) for the
acute and preventive treatment of migraine (EMA-approved
as Vydura® for the acute treatment of
migraine with or without aura, and prophylaxis of episodic migraine
in adults who have at least four migraine attacks per month) and a
broad pipeline of late-stage product candidates across five
distinct mechanistic platforms: CGRP receptor
antagonism for the acute and preventive treatment of migraine and
other CGRP-mediated diseases; glutamate modulation for
obsessive-compulsive disorder and spinocerebellar
ataxia; myeloperoxidase (MPO)
inhibition for amyotrophic lateral sclerosis; Kv7 ion
channel activators for focal epilepsy and neuronal
hyperexcitability, and myostatin inhibition for
neuromuscular diseases. More information about Biohaven
is available at
www.biohavenpharma.com.
NURTEC, NURTEC ODT and VYDURA are registered trademarks of
Biohaven Pharmaceutical Ireland DAC. Neuroinnovation is a trademark
of Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Contact:
Jennifer Porcelli
Vice President, Investor Relations
Jennifer.Porcelli@biohavenpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biohaven-to-discuss-first-quarter-2022-financial-results-and-recent-business-developments-on-may-11-2022-301542303.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.